Literature DB >> 15869804

Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice.

Shun Lv1, Jinping Zhang, Jin Wu, Xiujuan Zheng, Yiwei Chu, Sidong Xiong.   

Abstract

In the present investigation, we detected anti-dsDNA autoantibodies in cancer patients and modeled the production of anti-dsDNA autoantibodies by inoculating tumors in BALB/c mice. Moreover, induction of anti-dsDNA autoantibodies by immunization with inactivated tumor cells and their DNA indicated that DNA of tumor cells was probably the primary antigen, which was supported by the significantly increasing levels of sera free DNA in cancer patients and tumor-bearing mice. cELISA and indirect immunofluorescence assay showed that the anti-dsDNA autoantibodies could bind to the surface components of tumor cells. In vitro assay showed that immunosera at week 6 from immunized mice displayed significant cytotoxicity to tumor cells compared to that of negative control, but no cytotoxicity mediated by immunosera at week 22 was observed. In addition, by flow cytometry and electrophoresis of fragmented DNA, the cytotoxicity might probably be mediated by apoptosis. Our data also showed that the ability of the anti-dsDNA autoantibodies to induce apoptosis of SP2/0 and Wehi 164 cells was significantly correlated (r = 0.990, p < 0.01 and r = 0.901, p < 0.05) with their functional affinity. In vivo, the growth of solid tumors was significantly inhibited in the immunized mice inoculated directly with SP2/0 and Wehi 164 cells, or in the naïve mice which were inoculated with SP2/0 cells preincubated with immunosera containing anti-dsDNA autoantibodies. In conclusion, we demonstrated the origin of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. And our data also showed that these autoantibodies revealed anti-tumor effect by inducing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15869804     DOI: 10.1016/j.imlet.2005.03.019

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  12 in total

Review 1.  DNA as a self-antigen: nature and regulation.

Authors:  Chetna Soni; Boris Reizis
Journal:  Curr Opin Immunol       Date:  2018-09-24       Impact factor: 7.486

Review 2.  Systemic lupus erythematosus biomarkers: the challenging quest.

Authors:  Cristina Arriens; Jonathan D Wren; Melissa E Munroe; Chandra Mohan
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

Review 3.  Usage of cancer associated autoantibodies in the detection of disease.

Authors:  Steven P Dudas; Madhumita Chatterjee; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  IgG deposits can be detected in cell nuclei of patients with both lupus erythematosus and malignancy.

Authors:  Ingrid Böhm
Journal:  Clin Rheumatol       Date:  2007-03-16       Impact factor: 2.980

5.  The Role of IgM Antibodies in T Cell Lymphoma Protection in a Novel Model Resembling Anaplastic Large Cell Lymphoma.

Authors:  Chuancang Jiang; Ming-Lang Zhao; Luis Ramos; Katarzyna Dobaczewska; Ronald Herbert; Kristen Hobbie; Zbigniew Mikulski; Laurent Verkoczy; Marilyn Diaz
Journal:  J Immunol       Date:  2021-04-21       Impact factor: 5.422

6.  Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy.

Authors:  Lyse A Norian; Timothy P Kresowik; Henry M Rosevear; Britnie R James; Timothy R Rosean; Andrew J Lightfoot; Tamara A Kucaba; Christopher Schwarz; Christine J Weydert; Michael D Henry; Thomas S Griffith
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

7.  The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study.

Authors:  Jinyan Guo; Zhigang Ren; Jianhao Li; Tianfang Li; Shengyun Liu; Zujiang Yu
Journal:  Arthritis Res Ther       Date:  2020-06-26       Impact factor: 5.156

Review 8.  The dsDNA, Anti-dsDNA Antibody, and Lupus Nephritis: What We Agree on, What Must Be Done, and What the Best Strategy Forward Could Be.

Authors:  Ole Petter Rekvig
Journal:  Front Immunol       Date:  2019-05-15       Impact factor: 7.561

Review 9.  Autoimmunity and Gastric Cancer.

Authors:  Nicola Bizzaro; Antonio Antico; Danilo Villalta
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

10.  Systemic Lupus Erythematosus: Definitions, Contexts, Conflicts, Enigmas.

Authors:  Ole Petter Rekvig
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.